Pfizer Inc
NYSE: PFE
$26.72
-$0.32 (-1.2%)
Closing Price on November 8, 2024
PFE Articles
Investors love their dividends. So 24/7 Wall St. has tracked the Dogs of the Dow strategy for years now.
Published:
Last Updated:
The December 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
These six safer stocks all carry Merrill Lynch’s best volatility risk rating and pay dependable dividends. They offer reasonable entry points too.
Published:
Last Updated:
GlaxoSmithKline shares bounced higher on Wednesday after the company announced a new joint venture with Pfizer. These two firms will create a premier global consumer health care company combining...
Published:
Last Updated:
Elon Musk previews Los Angeles transportation tunnel, Pfizer and GlaxoSmithKline team up, stock buybacks hit a record this year, and other important business headlines today.
Published:
Last Updated:
These six Buy-rated stocks that have had a strong year and would be solid additions to portfolios for the end of 2018 and the beginning of 2019.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
The included top analyst upgrades, downgrades and initiations seen on Tuesday Apptio, AT&T, Bain Capital, Comerica, First Solar, Palo Alto Networks, Pfizer, Travelers and Ulta Beauty.
Published:
Last Updated:
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Now that 2018 is nearing an end, it is a serious time for investors to start thinking about expectations in 2019 rather than looking back at how choppy 2018 has been.
Published:
Last Updated:
24/7 Wall St. screened the Merrill Lynch research database for stocks rated Buy that pay a dividend and have the firm's best volatility risk rating. These five that look like solid picks for 2019 and...
Published:
Last Updated:
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Published:
Last Updated:
The demand for drugs to treat erectile dysfunction has risen to meet the needs of an aging population and to help combat disease-related causes.
Published:
Last Updated:
Caterpillar, UnitedHealth, Microsoft, and Pfizer lifted the down to 500-point gain Wednesday.
Published:
Last Updated:
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
Published:
Last Updated: